MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer

Cancer Letters

Volumn 373, Issue 1, 2016, Pages 130-137

  Fan, Pei ^a   Liu, Li ^a   Yin, Yefeng ^a   Zhao, Zhefu ^a   Zhang, Yiyao ^a   Amponsah, Prince S ^a   Xiao, Xi ^a   Bauer, Nathalie ^a   Abukiwan, Alia ^a   Nwaeburu, Clifford C ^a   Gladkich, Jury ^a   Gao, Chao ^a   Schemmer, Peter ^a   Gross, Wolfgang ^a   Herr, Ingrid ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemoresistance; Epigenetics; MicroRNA

Indexed keywords

GEMCITABINE; MICRORNA; MICRORNA 101 3P; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; MIRN101 MICRORNA, HUMAN; RRM1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BINDING SITE; CANCER RESISTANCE; CHEMOSENSITIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MIDDLE AGED; PANCREAS CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; DOSE RESPONSE; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE; UPREGULATION;

3' UNTRANSLATED REGIONS; ANTIMETABOLITES, ANTINEOPLASTIC; BINDING SITES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84958068760     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.01.038     Document Type: Article

References (26)

1. Stewart B.W., Wild C.P. World Cancer Report 2014 2014, WHO.
2. Cid-Arregui A., Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J. Gastroenterol 2015, 21:9297-9316.
3. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Madiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol 1997, 15:2403-2413.
4. Hung S.W., Mody H.R., Govindarajan R. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett 2012, 320:138-149.
5. Haenisch S., Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics 2012, 4:369-381.
6. Hasegawa S., Eguchi H., Nagano H., Konno M., Tomimaru Y., Wada H., et al. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br. J. Cancer 2014, 111:1572-1580.
7. Li Y., VandenBoom T.G., Kong D., Wang Z., Ali S., Philip P.A., et al. Up-regulation of miR-200 and let-by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009, 69:6704-6712.
8. Jordheim L.P., Seve P., Tredan O., Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 2011, 12:693-702.
9. Parker N.J., Begley C.G., Fox R.M. Human gene for the large subunit of ribonucleotide reductase (RRM1): functional analysis of the promoter. Genomics 1995, 27:280-285.
10. Shao J., Liu X., Zhu L., Yen Y. Targeting ribonucleotide reductase for cancer therapy. Expert Opin. Ther. Targets 2013, 17:1423-1437.
11. Huang P., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51:6110-6117.
12. Zhang X., Yashiro M., Qiu H., Nishii T., Matsuzaki T., Hirakawa K. Establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res 2010, 30:915-921.
13. Dong X., Hao Y., Wei Y., Yin Q., Du J., Zhao X. Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. PLoS ONE 2014, 9.
14. Wakai T., Shirai Y., Sakata J., Takamura M., Matsuda Y., Korita P.V., et al. Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2011, 58:1659-1663.
15. Nakahira S., Nakamori S., Tsujie M., Takahashi Y., Okami J., Yoshioka S., et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int. J. Cancer 2007, 120:1355-1363.
16. Wonganan P., Chung W.G., Zhu S.J., Kiguchi K., DiGiovanni J., Cui Z.R. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells. Cancer Biol. Ther 2012, 13:908-914.
17. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol 2006, 24:4731-4737.
18. Yoneyama H., Takizawa-Hashimoto A., Takeuchi O., Watanabe Y., Atsuda K., Asanuma F., et al. Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones. Anticancer Drugs 2015, 26:90-100.
19. Hage C., Rausch V., Giese N., Giese T., Schonsiegel F., Labsch S., et al. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis 2013, 4:e627.
20. Gassler N., Zhang C., Schnabel P.A., Dienemann H., Debatin K.-M., Mattern J., et al. Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Brit J Cancer 2005, 92:1084-1088.
21. Kallifatidis G., Rausch V., Baumann B., Apel A., Beckermann B.M., Groth A., et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009, 58:949-963.
22. Takikita M., Altekruse S., Lynch C.F., Goodman M.T., Hernandez B.Y., Green M., et al. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res 2009, 69:2950-2955.
23. Bao B., Ali S., Banerjee S., Wang Z.W., Logna F., Azmi A.S., et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 2012, 72:335-345.
24. Chang Z., Huo L., Li K., Wu Y., Hu Z. Blocked autophagy by miR-101 enhances osteosarcoma cell chemosensitivity in vitro. Sc World J. 2014, 2014:794756.
25. Xu Y., An Y., Wang Y., Zhang C., Zhang H., Huang C., et al. miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol. Rep 2013, 29:2019-2024.
26. Caponi S., Funel N., Frampton A.E., Mosca F., Santarpia L., Van der Velde A.G., et al. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann. Oncol 2013, 24:734-741.